Literature DB >> 7376643

Single daily dose methimazole treatment of hyperthyroidism.

D J Bouma, H Kammer.   

Abstract

The effectiveness of methimazole used in a single daily dose was studied in 47 patients during their initial episode of hyperthyroidism, and in an additional eight patients during a relapse of hyperthyroidism. All patients become euthyroid using this method. Mean time required to achieve a euthyroid state was 16.7+/-1.1 weeks in the former group, and 14.9+/-2.9 weeks in the latter. In one patient there was an initial response to single daily dose therapy, but subsequently split dosage was required for control. The single daily dose regimen of antithyroid drugs will control hyperthyroidism in most patients. We have found that propylthiouracil will achieve this more rapidly than methimazole.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7376643      PMCID: PMC1271936     

Source DB:  PubMed          Journal:  West J Med        ISSN: 0093-0415


  9 in total

1.  TREATMENT OF HYPERTHYROIDISM WITH A SINGLE DAILY DOSE OF PROPYLTHIOURACIL.

Authors:  M A GREER; W C MEIHOFF; H STUDER
Journal:  N Engl J Med       Date:  1965-04-29       Impact factor: 91.245

2.  Effect of antithyroid agents 6-propyl-2-thiouracil and 1-mehtyl-2-mercaptoimidazole on human thyroid iodine peroxidase.

Authors:  A Nagasaka; H Hidaka
Journal:  J Clin Endocrinol Metab       Date:  1976-07       Impact factor: 5.958

3.  A simple test for selecting the thioamide schedule in thyrotoxicosis.

Authors:  H V Barnes; T Bledsoe
Journal:  J Clin Endocrinol Metab       Date:  1972-08       Impact factor: 5.958

4.  The use of antithyroid drugs in a single daily dose. Treatment of diffuse toxic goiter.

Authors:  H Kammer; K Srinivasan
Journal:  JAMA       Date:  1969-09-01       Impact factor: 56.272

5.  Classification of the eye changes of Grave's disease.

Authors:  S C Werner
Journal:  J Clin Endocrinol Metab       Date:  1969-07       Impact factor: 5.958

6.  Altered plasma half-lives of antipyrine, propylthiouracil, and methimazole in thyroid dysfunction.

Authors:  E S Vesell; J R Shapiro; T Passananti; H Jorgensen; C A Shively
Journal:  Clin Pharmacol Ther       Date:  1975-01       Impact factor: 6.875

7.  35-S-antithyroid drug concentration and organic binding of iodine in the human thyroid.

Authors:  J H Lazarus; B Marchant; W D Alexander; D H Clark
Journal:  Clin Endocrinol (Oxf)       Date:  1975-11       Impact factor: 3.478

8.  Prospective randomized comparison of propylthiouracil.

Authors:  G Gwinup
Journal:  JAMA       Date:  1978-06-09       Impact factor: 56.272

9.  Short-term antithyroid drug therapy for the thyrotoxicosis of Graves's disease.

Authors:  M A Greer; H Kammer; D J Bouma
Journal:  N Engl J Med       Date:  1977-07-28       Impact factor: 91.245

  9 in total
  3 in total

1.  Role of colestipol in the treatment of hyperthyroidism.

Authors:  P Hagag; H Nissenbaum; M Weiss
Journal:  J Endocrinol Invest       Date:  1998-12       Impact factor: 4.256

2.  Current and emerging treatment options for Graves' hyperthyroidism.

Authors:  Prakash Abraham; Shamasunder Acharya
Journal:  Ther Clin Risk Manag       Date:  2010-02-02       Impact factor: 2.423

3.  Efficacy of Once Daily versus Divided Daily Administration of Low Daily Dosage (15 mg/Day) of Methimazole in the Induction of Euthyroidism in Graves' Hyperthyroidism: A Randomized Controlled Study.

Authors:  Sutin Sriussadaporn; Wanwaroon Pumchumpol; Raweewan Lertwattanarak; Tada Kunavisarut
Journal:  Int J Endocrinol       Date:  2017-12-18       Impact factor: 3.257

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.